Objectives: many studies have shown that oral beta blockers reduce the incidence of atrial fibrillation after coronary artery bypass. The goal of this study was to determine whether landiolol, an intravenous beta blocker, reduces the incidence of atrial fibrillation after off-pump coronary artery bypass.
Methods: 39 consecutive patients were given landiolol after coronary artery bypass, and 20 who were not given landiolol served as a control group. Landiolol was intravenously administered at 1 µgċkg−1ċmin−1 in the intensive care unit.
Results: the mean dose of landiolol was 2.3 ± 1.2 1 µgċkg−1ċmin−1. The incidence of atrial fibrillation during intensive care unit stay was significantly lower in the landiolol group compared to the control group: 2.6% (1/39) vs. 20% (4/20). Heart rate after landiolol administration was significantly lower than that before administration, whereas landiolol had no effect on blood pressure. C-reactive protein and creatine kinase levels 7 days after surgery were significantly lower in the landiolol group.
Conclusion: continuous administration of landiolol at a low dose after off-pump coronary artery bypass reduced the incidence of atrial fibrillation.
FullerJAAdamsGGBuxtonB. Atrial fibrillation after coronary artery bypass grafting: is it a disorder of the elderly?J Thorac Cardiovasc Surg1989; 97: 821–825.
2.
CoxJL. A perspective of postoperative atrial fibrillation in cardiac operations. Ann Thorac Surg1993; 56: 405–409.
3.
RubinDANieminskiKEReedGEHermanMV. Predictors, prevention, and long-term prognosis of atrial fibrillation after coronary artery bypass graft operations. J Thorac Cardiovasc Surg1987; 94: 331–335.
4.
StrakaZWidimskyPJirasekKStrosPVotavaJVanekT. Off-pump versus on-pump coronary surgery: final results from a prospective randomized study PRAGUE-4. Ann Thorac Surg2004; 77: 789–793.
5.
GerolaLRBuffoloEJasbikWBotelhoBBoscoJBrasilLA. Off-pump versus on-pump myocardial revascularization in low-risk patients with one or two vessel disease: perioperative results in a multicenter randomized controlled trial. Ann Thorac Surg2004; 77: 569–573.
6.
PuskasJDWilliamsWHDukePGStaplesJRGlasKEMarshallJJ. Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, transfusion requirements, and length of stay: a prospective randomized comparison of two hundred unselected patients undergoing off-pump versus conventional coronary artery bypass grafting. J Thorac Cardiovasc Surg2003; 125: 797–808.
7.
LégaréJFButhKJKingSWoodJSullivanJAHancock FriesenC. Coronary bypass surgery performed off pump does not result in lower in-hospital morbidity than coronary artery bypass grafting performed on pump. Circulation2004; 109: 887–892.
8.
MøllerCHPerkoMJLundJTAndersenLWKelbaekHMadsenJK. No major differences in 30-day outcomes in high-risk patients randomized to off-pump versus on-pump coronary bypass surgery: the best bypass surgery trial. Circulation2010; 121: 498–504.
9.
VillarealRPHariharanRLiuBCKarBLeeVVElaydaM. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol2004; 43: 742–748.
10.
Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110;e340–e437.
11.
DunningJTreasureTVersteeghMNashefSA. EACTS Audit and Guidelines Committee. Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg2006; 30: 852–872.
12.
ArankiSFShawDPAdamsDHRizzoRJCouperGSVan der VlietM. Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. Circulation1996; 94: 390–397.
13.
BradleyDCreswellLLHogueCWJrEpsteinAEPrystowskyENDaoudEG. Pharmacologic prophylaxis: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest2005; 128: 39S–47S.
14.
FujiwaraHSakuraiMNamaiAKawamuraT. Effect of low-dose landiolol, an ultrashort-acting beta-blocker, on postoperative atrial fibrillation after CABG surgery. Gen Thorac Cardiovasc Surg2009; 57: 132–137.
15.
Morishima A, Hirao S, Nagasaka S, Yokoyama S, Kaneda K, Nishiwaki N. Suppressive effect of landiolol hydrochloride on atrial fibrillation following surgical repair of acute type A aortic dissection. Jpn J Vasc Surg 2009;18:481–5. Available at: https://www.jstage.jst.go.jp/article/jsvs/18/4/18_4_481/_article/-char/ja/. Accessed May 16, 2012.
16.
OkitaTUjiMShinjoTMoriokaMKumanoHIshimuraN. Use of landiolol hydrochloride for the prevention of atrial fibrillation after lung resection. Masui2008; 57: 953–958.
17.
SezaiAMinamiKNakaiTHataMYoshitakeIWakuiS. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. J Thorac Cardiovasc Surg2011; 141: 1478–1487.
18.
Shimomura T, Usui A, Ueda Y. Involvement of sympathetic activity in the onset of atrial fibrillation following cardiac surgery. Jpn J Cardiovasc Surg 2006;35:309–14. Available at: https://www.jstage.jst.go.jp/browse/jjcvs/35/0/_contents. Accessed May 16, 2012.
19.
ChungMKMartinDOSprecherDWazniOKanderianACarnesCA. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation2001; 104: 2886–2891.
20.
IshidaKKimuraFImamakiMIshidaAShimuraHKohnoH. Relation of inflammatory cytokines to atrial fibrillation after off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg2006; 29: 501–505.
21.
HagiwaraSIwasakaHMaedaHNoguchiT. Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. Shock2009; 31: 515–520.
22.
SasaoJTarverSDKindscherJDTaneyamaCBensonKTGotoH. In rabbits, landiolol, a new ultra-short-acting β-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can J Anesth2001; 48: 985–989.
23.
IguchiSIwamuraHNishizakiMHayashiASenokuchiKKobayashiK. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull (Tokyo)1992; 40: 1462–1469.
